AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 34.77 USD 2.81% Market Closed
Market Cap: 973.6m USD

AnaptysBio Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AnaptysBio Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Cash from Operating Activities
-$145m
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
-38%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
958.8m USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
44.65 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's Cash from Operating Activities?
Cash from Operating Activities
-145m USD

Based on the financial report for Sep 30, 2025, AnaptysBio Inc's Cash from Operating Activities amounts to -145m USD.

What is AnaptysBio Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-38%

Over the last year, the Cash from Operating Activities growth was -41%. The average annual Cash from Operating Activities growth rates for AnaptysBio Inc have been -18% over the past three years , -17% over the past five years , and -38% over the past ten years .

Back to Top